Sign In to Follow Application
View All Documents & Correspondence

Ph Dependent Anti Sulfated Glycosaminoglycan Antibody And Antibody Drug Conjugate

Abstract: Provided is an antibody that exhibits pH dependence and specifically binds to a sulfated glycosaminoglycan (sGAG). An antibody specifically binding to a sulfated glycosaminoglycan that is at least one selected from the group consisting of the following (1) to (3): (1) an antibody that contains a heavy chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 1, CDR2 comprising an amino acid sequence represented by SEQ ID NO: 2 and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 3, and a light chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 4, CDR2 comprising an amino acid sequence represented by LGS and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 6; (2) an antibody that contains a heavy chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 7, CDR2 comprising an amino acid sequence represented by SEQ ID NO: 8 and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 9, and a light chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 10, CDR2 comprising an amino acid sequence represented by AAS and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 12; and (3) an antibody that contains a heavy chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 13, CDR2 comprising an amino acid sequence represented by SEQ ID NO: 14 and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 15, and a light chain having CDR1 comprising an amino acid sequence represented by SEQ ID NO: 16, CDR2 comprising an amino acid sequence represented by WAS and CDR3 comprising an amino acid sequence represented by SEQ ID NO: 18.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
16 October 2024
Publication Number
51/2024
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
Parent Application

Applicants

THE UNIVERSITY OF TOKYO
3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654
TAIHO PHARMACEUTICAL CO., LTD.
1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo 1018444

Inventors

1. ISHIKAWA Shumpei
c/o The University of Tokyo, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654
2. KATOH Hiroto
c/o The University of Tokyo, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654
3. FURUYA Genta
c/o The University of Tokyo, 3-1, Hongo 7-chome, Bunkyo-ku, Tokyo 1138654
4. SENGA Shogo
c/o TAIHO PHARMACEUTICAL CO., LTD., 3, Okubo, Tsukuba-shi, Ibaraki 3002611

Specification

Documents

Application Documents

# Name Date
1 202417078684-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [16-10-2024(online)].pdf 2024-10-16
2 202417078684-STATEMENT OF UNDERTAKING (FORM 3) [16-10-2024(online)].pdf 2024-10-16
5 202417078684-Sequence Listing in PDF [16-10-2024(online)].pdf 2024-10-16
6 202417078684-REQUEST FOR EXAMINATION (FORM-18) [16-10-2024(online)].pdf 2024-10-16
7 202417078684-PROOF OF RIGHT [16-10-2024(online)].pdf 2024-10-16
8 202417078684-PRIORITY DOCUMENTS [16-10-2024(online)].pdf 2024-10-16
9 202417078684-POWER OF AUTHORITY [16-10-2024(online)].pdf 2024-10-16
10 202417078684-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [16-10-2024(online)].pdf 2024-10-16
11 202417078684-FORM 18 [16-10-2024(online)].pdf 2024-10-16
12 202417078684-FORM 1 [16-10-2024(online)].pdf 2024-10-16
13 202417078684-DRAWINGS [16-10-2024(online)].pdf 2024-10-16
14 202417078684-DECLARATION OF INVENTORSHIP (FORM 5) [16-10-2024(online)].pdf 2024-10-16
15 202417078684-COMPLETE SPECIFICATION [16-10-2024(online)].pdf 2024-10-16
16 202417078684-Others-251124.pdf 2024-11-28
17 202417078684-Others-251124-1.pdf 2024-11-28
18 202417078684-GPA-251124.pdf 2024-11-28
19 202417078684-Correspondence-251124.pdf 2024-11-28
20 202417078684-FORM 3 [08-04-2025(online)].pdf 2025-04-08